Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.cnbc.com — the content belongs to CNBC.